0000899243-20-003398.txt : 20200205 0000899243-20-003398.hdr.sgml : 20200205 20200205193125 ACCESSION NUMBER: 0000899243-20-003398 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fishman Mark CENTRAL INDEX KEY: 0001786003 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 20580470 MAIL ADDRESS: STREET 1: C/O BEAM THERAPEUTICS INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-02-05 0 0001745999 Beam Therapeutics Inc. BEAM 0001786003 Fishman Mark C/O BEAM THERAPEUTICS INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 0 0 0 Series A-1 Preferred Stock Common Stock 15768 D Series A-1 Preferred Stock Common Stock 1239 D Stock Option (Right to Buy) 0.67 2028-05-08 Common Stock 102580 D Stock Option (Right to Buy) 0.67 2028-05-08 Common Stock 64670 D Stock Option (Right to Buy) 1.03 2028-07-13 Common Stock 36126 D Stock Option (Right to Buy) 1.03 2028-07-13 Common Stock 56865 D Each share of Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the registrant, for no additional consideration. There is no expiration date for the Preferred Stock. The option vested as to 25% on the first anniversary of the of the vesting commencement date, April 30, 2018, and at a rate of 8.33% each quarter thereafter until the option is fully vested. The option vested as to 25% on the first anniversary of the of the vesting commencement date, May 11, 2018, and at a rate of 8.33% each quarter thereafter until the option is fully vested. The option vested as to 25% on the first anniversary of the of the vesting commencement date, May 11, 2018, and at a rate of 8.33% each quarter thereafter until the option is fully vested. The option vested as to 25% on the first anniversary of the of the vesting commencement date, May 8, 2018, and at a rate of 8.33% each quarter thereafter until the option is fully vested. Exhibit List: Exhibit 24 - Power of Attorney By: /s/ Christine Bellon, Attorney-in-Fact 2020-02-05 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints John Evans and Christine
Bellon, and each of them individually, with full power of substitution, as the
undersigned's true and lawful attorney-in-fact to:

        (1)   prepare, execute in the undersigned's name and on the
              undersigned's behalf, and submit to the U.S. Securities and
              Exchange Commission (the "SEC") a Form ID, including amendments
              thereto, and any other documents necessary or appropriate to
              obtain codes and passwords enabling the undersigned to make
              electronic filings with the SEC of reports required by Section
              16(a) of the Securities Exchange Act of 1934, as amended, or any
              rule or regulation of the SEC;

        (2)   execute for and on behalf of the undersigned, in the undersigned's
              capacity as officer and/or director of Beam Therapeutics Inc. (the
              "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
              accordance with Section 16(a) of the Securities Exchange Act of
              1934, as amended, and the rules thereunder;

        (3)   do and perform any and all acts for and on behalf of the
              undersigned that may be necessary or desirable to complete and
              execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
              and execute any amendment or amendments thereto, and timely file
              such form with the SEC and any stock exchange or similar
              authority; and

        (4)   take any other action of any type whatsoever in connection with
              the foregoing that, in the opinion of each such attorney-in-fact,
              may be of benefit to, in the best interest of, or legally required
              by, the undersigned, it being understood that the documents
              executed by each such attorney-in-fact on behalf of the
              undersigned pursuant to this Power of Attorney shall be in such
              form and shall contain such terms and conditions as each such
              attorney-in-fact may approve in each such attorney-in-fact's
              discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or each such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted.  The undersigned acknowledges that each
foregoing attorney-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                      [Remainder of page intentionally left blank]



        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 7th day of August, 2019.


                                        /s/ Mark Fishman
                                        ----------------------------------------
                                        Name: Mark Fishman